EP0668875A4 - Auf blutgerinnsel gerichtetes antikoagulanz, verfahren zur herstellung desselben und zu seiner verwendung. - Google Patents

Auf blutgerinnsel gerichtetes antikoagulanz, verfahren zur herstellung desselben und zu seiner verwendung.

Info

Publication number
EP0668875A4
EP0668875A4 EP93922464A EP93922464A EP0668875A4 EP 0668875 A4 EP0668875 A4 EP 0668875A4 EP 93922464 A EP93922464 A EP 93922464A EP 93922464 A EP93922464 A EP 93922464A EP 0668875 A4 EP0668875 A4 EP 0668875A4
Authority
EP
European Patent Office
Prior art keywords
clot
anticoagulant
directed
methods
making same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93922464A
Other languages
English (en)
French (fr)
Other versions
EP0668875A1 (de
Inventor
Paul Eisenberg
Dennis Brian Rylatt
Carmel Judith Hillyard
Peter Gregory Bundesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agen Ltd
Original Assignee
Agen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agen Ltd filed Critical Agen Ltd
Publication of EP0668875A1 publication Critical patent/EP0668875A1/de
Publication of EP0668875A4 publication Critical patent/EP0668875A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
EP93922464A 1992-10-12 1993-10-12 Auf blutgerinnsel gerichtetes antikoagulanz, verfahren zur herstellung desselben und zu seiner verwendung. Withdrawn EP0668875A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPL5234/92 1992-10-12
AUPL523492 1992-10-12
PCT/AU1993/000524 WO1994009034A1 (en) 1992-10-12 1993-10-12 Clot directed anticoagulant, process for making same and methods of use

Publications (2)

Publication Number Publication Date
EP0668875A1 EP0668875A1 (de) 1995-08-30
EP0668875A4 true EP0668875A4 (de) 1999-05-26

Family

ID=3776468

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93922464A Withdrawn EP0668875A4 (de) 1992-10-12 1993-10-12 Auf blutgerinnsel gerichtetes antikoagulanz, verfahren zur herstellung desselben und zu seiner verwendung.

Country Status (3)

Country Link
EP (1) EP0668875A4 (de)
WO (1) WO1994009034A1 (de)
ZA (1) ZA937553B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US6518244B2 (en) 2000-03-09 2003-02-11 Intimax Corporation Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2450828C (en) 2001-06-26 2013-11-26 Agen Biomedical Limited Humanized antibodies derived from dd-3b6/22, specific for the d-dimer fragment of fibrin
US20050261241A1 (en) 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
JP2008509666A (ja) * 2004-08-11 2008-04-03 トルビオン・ファーマシューティカルズ・インコーポレイテッド 結合ドメイン融合タンパク質
PL1912675T3 (pl) 2005-07-25 2014-10-31 Emergent Product Dev Seattle Zmniejszanie liczby komórek B za pomocą cząsteczek wiążących swoistych dla antygenów CD37 i CD20
WO2007092447A2 (en) * 2006-02-06 2007-08-16 Burnham Institute For Medical Research Methods and compositions related to targeting tumors and wounds
MX363905B (es) 2006-06-12 2019-04-08 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
WO2009126944A1 (en) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
KR101841870B1 (ko) 2008-05-16 2018-03-23 바이엘 헬스케어 엘엘씨 표적화 응고 인자 및 그의 사용 방법
JP7002446B2 (ja) 2015-09-21 2022-03-04 アプティーボ リサーチ アンド デベロップメント エルエルシー Ｃｄ３結合ポリペプチド
TW201831508A (zh) 2016-11-16 2018-09-01 美商拜耳保健有限責任公司 紅血球標靶因子ｖｉｉｉ及其使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001332A1 (en) * 1988-08-10 1990-02-22 Cetus Corporation Plasminogen activator-heparin conjugates
WO1990006133A1 (en) * 1988-11-25 1990-06-14 Centocor, Inc. Heterobifunctional antibodies having specificity for platelets and thrombolytic agents
WO1990011783A1 (en) * 1989-04-03 1990-10-18 Centocor, Inc. Platelet specific immunoconjugates

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017379A (en) * 1984-05-25 1991-05-21 Lemelson Jerome H Drug units and methods for treating blood clots
NL8901102A (nl) * 1989-05-01 1990-12-03 Tno Antilichamen tegen fibrine; voor de bereiding van de antilichamen geschikte immunogene peptiden, werkwijze voor het bepalen van fibrine en farmaceutisch preparaat op basis van de antilichamen.
IE901736L (en) * 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
AU636909B2 (en) * 1989-08-24 1993-05-13 Australian Nuclear Science & Technology Organisation Radio-labelled antibodies for imaging
WO1991016353A1 (en) * 1990-04-23 1991-10-31 Corvas International N.V. Thrombus-specific antibody derivatives
WO1993007174A1 (en) * 1991-10-01 1993-04-15 The General Hospital Corporation Activation-dependent protein expressed on the surface of activated platelets and antibodies thereto

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001332A1 (en) * 1988-08-10 1990-02-22 Cetus Corporation Plasminogen activator-heparin conjugates
WO1990006133A1 (en) * 1988-11-25 1990-06-14 Centocor, Inc. Heterobifunctional antibodies having specificity for platelets and thrombolytic agents
WO1990011783A1 (en) * 1989-04-03 1990-10-18 Centocor, Inc. Platelet specific immunoconjugates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9409034A1 *

Also Published As

Publication number Publication date
ZA937553B (en) 1994-05-03
WO1994009034A1 (en) 1994-04-28
EP0668875A1 (de) 1995-08-30

Similar Documents

Publication Publication Date Title
EP0634113A3 (de) Tabakrauchfilter und Verfahren zu deren Herstellung.
PL320692A1 (en) Novel anticoagulant, method of obtaining same and application thereof
GR3034647T3 (en) Test article and method for performing blood coagulation assays.
DE3876886D1 (de) Plasmasammelsatz und verfahren.
EP0758247A4 (de) O-desulfatierte heparin-derivate, verfahren zu deren herstellung und verwendungen
EP0647439A3 (de) Poröse Gegenstände und Verfahren zu ihrer Herstellung.
NO179033C (no) Tampong, samt fremgangsmåte og innretning for fremstilling av samme
IL73159A0 (en) Carboxyalkenamidocephalosporines,process for the preparation thereof and methods for the use thereof
AU616091B2 (en) Treatment process
EP0690457A3 (de) Polyaniline-Lösung, damit beschichtete Gegenstände und Verfahren zur Herstellung derselben
AU7750494A (en) Composites and methods for making same
EP0657403A4 (de) Poröses keramisches material und verfahren zu seiner herstellung.
EP0653392A4 (de) Poröse keramik und verfahren zu ihrer herstellung.
EP0668875A4 (de) Auf blutgerinnsel gerichtetes antikoagulanz, verfahren zur herstellung desselben und zu seiner verwendung.
AR244574A1 (es) Un adsorbente con base de alumina para la purificacion de olefinas y procedimiento para prepararlo.
PH31312A (en) Polyolefin article and method of making.
EP0435171A3 (en) Sliding property improving agent and process for making the same
AU4090289A (en) Method for the treatment of wool
ZA834460B (en) 2,3-difluoro-5-(trifluoromethyl)pyridine and methods of making and using the same
EP0630383A4 (de) Methoden zur behandlung von diabetis.
AU3799889A (en) New heteropolysaccharide, process for its manufacture and its use
EP0565720A4 (de) Poröse faser und verfahren zu deren herstellung.
AU3767289A (en) Yarn, and method of manufacture and use thereof
EP0665435A3 (de) Verfahren zur Bestimmung von Gerinnungsparametern.
DE3874672D1 (de) Verfahren zur oxydierung von thiolen, disulfiden und thiolsulfonaten.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950512

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE FR GB IT LI

RHK1 Main classification (correction)

Ipc: C07K 14/00

A4 Supplementary search report drawn up and despatched

Effective date: 19990409

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): CH DE FR GB IT LI

17Q First examination report despatched

Effective date: 19990805

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000216